BTK and B-cell chronic lymphocytic leukemia: BTK inhibitors, by targeting Bruton tyrosine kinase, disrupt B-cell receptor signaling to inhibit B-cell proliferation and survival and are widely used in B-cell malignancies such as Chronic lymphocytic leukemia/small lymphocytic lymphoma and MCL (6).